Medical device developers are designing products that boost treatment adherence and increase positive health outcomes. Merck, for example, aims to simplify treatment through its pen-shaped device line and thus increasing adherence.
Adherence to therapies is a primary determinant of treatment success, according to the Oman Medical Journey. Failure to adhere to a prescribed treatment is a serious problem that not only affects the patient but the healthcare system. Medication nonadherence in patients leads to substantial worsening of disease, death and increased healthcare costs. Furthermore, assessing patient adherence to medication is necessary to distinguish between nonadherence and inferior drug efficacy, explains RTI Health Solutions.
Providing better-designed medical devices is only part of the challenge to overcome poor treatment-adherence. “Even the best medical-grade sensors and therapeutic delivery mechanisms in the world are useless if the devices they are embedded in are not used consistently and properly,” says Medtech Intelligence.
If used properly, drug delivery medical devices can provide localized continuous treatment, reduce systemic toxicity, improve patient compliance and deliver drugs that are incompatible with oral formulations.
Merck is developing a line of patient-accessible medical devices that deliver drugs through a line of “pen-shaped devices that are safe and comfortable to use, leading to easier application and higher adherence to treatment,” Alfredo Román, Director of the Fertility Unit, Merck Group México, told MBN.
Merck’s pen-shaped devices make it easier for patients to adhere to treatment, which is a global issue for any pharmaceutical company. For example, “in fertility, adherence becomes even more challenging because almost every solution in the market consists of products for intramuscular application, which are harder to apply,” he said.
“Merck carefully assessed their patients’ needs using knowledge gained from working with the community for many decades to identify new solutions,” said Luciano Rossetti, Head of Global Research and Development, Merck, in an official communicate. Its pen shaped devices were developed with a focus on improving the patient treatment experience.